Mankind Pharma reported a robust 38% year-on-year increase in its Q2 FY27 , reaching ₹716 crore. This impressive growth was fueled by strong performance in both its domestic and export markets, alongside an expansion in s.
₹716 crore
Net Profit (Q2 FY27)
Q2 FY26: ₹519 crore→₹716 crore
⏳ Time Machine
How today’s news fits into the bigger picture
1995
Mankind Pharma Founded
Mankind Pharma was established with a mission to provide affordable healthcare to the masses, focusing on a strong presence in rural and semi-urban markets across India.
Early 2010s
Entry into Consumer Healthcare
The company diversified into the fast-growing consumer healthcare segment with popular over-the-counter brands, significantly expanding its market reach beyond prescription drugs.
2020
Pandemic-Driven Demand Surge
Like many pharmaceutical companies, Mankind Pharma experienced increased demand for its products during the COVID-19 pandemic, leading to a boost in sales and revenue, reinforcing its market position.
2023
Successful IPO Launch
Mankind Pharma went public with a highly successful Initial Public Offering (IPO), valuing the company at over ₹43,000 crore ($5.2 billion) and attracting significant investor interest, making it one of the largest pharma IPOs.
Last Quarter (Q1 FY27)
Continued Healthy Growth
The company reported continued healthy revenue and profit growth in Q1 FY27, maintaining positive momentum that set the stage for the strong performance seen in the current quarter.
Today
Mankind Pharma reported a 38% YoY rise in Q2 FY27 net profit to ₹716 crore.
What happens next?
Mankind Pharma is expected to continue focusing on expanding its product portfolio and market presence, with investors looking for sustained growth and margin improvement in upcoming quarters.
Mankind Pharma, a leading Indian pharmaceutical company, announced strong financial results for the second quarter of Fiscal Year 2027, with net profit surging by **38%** year-on-year to **₹716 crore**. The company also reported a **17%** rise in revenue during the same period. This robust performance was attributed to healthy growth across its core domestic markets and a solid contribution from its export business. Furthermore, Mankind Pharma's operational efficiency improved significantly, with its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margins expanding by **210 basis points**. The positive results indicate strong demand for its pharmaceutical products and over-the-counter brands, bolstering investor confidence.
💭 If you're wondering…
Q2 FY27 refers to the second quarter of the fiscal year 2027. In India, the fiscal year typically runs from April 1 to March 31, so Q2 would cover the period from July 1 to September 30, 2026.
Did this story help?
Knowledge Chain — tap a concept